via National Cancer Institute
- Test proved able to detect and indicate site of dozens of types of cancer with high accuracy according to recent study
- Dana-Farber joins multi-center trial to provide test results to patients for the first time
In a study involving thousands of participants, a new blood test detected more than 50 types of cancer as well as their location within the body with a high degree of accuracy, according to an international team of researchers led by Dana-Farber Cancer Institute and the Mayo Clinic.
The results, published online today by the Annals of Oncology, indicate that the test – which identified some particularly dangerous cancers that lack standard approaches to screening – can play a key role in early detection of cancer. Early detection can often be critical to successful treatment.
Developed by GRAIL, Inc., of Menlo Park, Calif., the test uses next-generation sequencing to analyze the arrangement of chemical units called methyl groups on the DNA of cancer cells. Adhering to specific sections of DNA, methyl groups help control whether genes are active or inactive. In cancer cells, the placement of methyl groups, or methylation pattern, is often markedly different from that of normal cells – to the extent that abnormal methylation patterns are even more characteristic of cancer cells than genetic mutations are. When tumor cells die, their DNA, with methyl groups firmly attached, empties into the blood, where it can be analyzed by the new test.
“Our previous work indicated that methylation-based tests outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples,” said Dana-Farber’s Geoffrey Oxnard, MD, co-lead author of the study with Minetta Liu, MD, of the Mayo Clinic. “The results of this study suggest that such assays could be a feasible way of screening people for a wide variety of cancers.”
In the study, investigators used the test to analyze cell-free DNA (DNA from normal and cancerous cells that had entered the bloodstream upon the cells’ death) in 6,689 blood samples, including 2,482 from people diagnosed with cancer and 4,207 from people without cancer. The samples from patients with cancer represented more than 50 cancer types, including breast, colorectal, esophageal, gallbladder, bladder, gastric, ovarian, head and neck, lung, lymphoid leukemia, multiple myeloma, and pancreatic cancer.
The overall specificity of the test was 99.3%, meaning that only 0.7% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for 12 cancers that account for nearly two-thirds of U.S. cancer deaths was 67.3%, meaning the test could find the cancer two-thirds of the time but a third of the time the test returned a negative result. Within this group, the sensitivity was 39% for patients with stage I cancer, 69% for those with stage II, 83% for those with stage III, and 92% for those with stage IV. The stage I-III sensitivity across all 50 cancer types was 43.9%. When cancer was detected, the test correctly identified the organ or tissue where the cancer originated in more than 90% of cases – critical information for determining how the disease is diagnosed and managed.
“Our results show that this approach to testing cell-free DNA in blood can detect a broad range of cancer types at virtually any stage of the disease, with specificity and sensitivity approaching the level needed for population-level screening,” Oxnard observed. “The test can be an important part of clinical trials for early cancer detection.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Cancer test
- Honey Boo Boo’s Sister Anna Diagnosed With Stage 4 Cancer, Mama June By Her Side
An insider claimed she visited the doctors after experiencing stomach issues. The doctors ran a series of tests and found cancer in her liver, kidney, and lung. The reality star has undergone her ...
- Blood tests may spare cancer patients chemo
A major bowel cancer trial is examining whether the test can show if surgery has removed all of the tumour. Doctors say half of patients with stage 3 bowel cancer are cured by surgery alone so by ...
- BGI Genomics partners with Zentya to launch fecal DNA test for colorectal cancer in Slovakia
COLOTECT TM 1.0 is one of the first-ever fecal DNA tests for colorectal cancer that is available in the country. It is a non-invasive fecal DNA test developed by BGI Genomics for detecting colorectal ...
- New hope for bowel cancer patients as blood test could spare patients chemotherapy
New hope for bowel cancer patients as blood test could spare patients chemotherapy - Doctors say half of patients with stage 3 bowel cancer are cured by surgery alone ...
- This Blood Test Targets 50 Types of Cancer
Grail’s Galleri aims to screen for many more types of tumor than was previously possible. Large-scale clinical trials are underway.
Go deeper with Google Headlines on:
Cancer test
[google_news title=”” keyword=”cancer test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Cancer blood test
- New hope for bowel cancer patients as blood test could spare patients chemotherapy
A new blood test could spare bowel cancer patients from undergoing unnecessary chemotherapy every year. About 1,600 bowel cancer patients in the UK are set to take part in a study over four years, ...
- This Blood Test Targets 50 Types of Cancer
Grail’s Galleri aims to screen for many more types of tumor than was previously possible. Large-scale clinical trials are underway.
- Chesapeake firefighters receive cancer screening
With firefighters at least three times more likely to develop cancer and 14% more likely to die from cancer than the rest of the general population, the Chesapeake Fire Department hopes a ...
- ‘Blood test meant I was spared chemo’
A blood test which can detect traces of cancer cells could spare thousands of patients unnecessary chemotherapy every year. A major bowel cancer trial is examining whether the test can show if surgery ...
- Blood tests may spare cancer patients chemo
The blood tests work by looking for microscopic traces of cancer in the bloodstream called circulating tumour DNA. The presence of these markers indicates whether the patient has ...
Go deeper with Google Headlines on:
Cancer blood test
[google_news title=”” keyword=”cancer blood test” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]